The world-renowned transformative medicine expert will contribute towards Mind Cure's work in the realm of psychedelic research, treatment and integration
Psychedelics
Field Trip Psychedelics Inc. Announces Successful GLP Synthesis, Results From Initial Preclinical Testing for FT-104, its First Molecule in Development
Field Trip announces testing of its first synthesized psychedelics molecule.
Mind Cure Adds Two-Time Female Entrepreneur of The Year As New COO
Mind Cure's new Chief Operating Officer has already launched several successful businesses.
Mind Cure (CSE: MCUR) Announces Kelsey Ramsden as new Chief Operating Officer
The company bolsters its executive team with the addition of an industry leader and experienced entrepreneur
Mind Cure Adds High-Profile Female As New COO
Mind Cure's new Chief Operating Officer has already launched several successful businesses.
Will MindMed Be The Next Billion-Dollar Psychedelic Stock?
With trading volumes going through the roof and a potential NASDAQ listing, will MindMed be the next billion-dollar psychedelics company?
Why Is Kevin O’Leary So Bullish On Psychedelics?
Kevin O’Leary won’t touch cannabis as an investment but he loves the potential of psychedelic drugs. Why?
Mindleap Health Announces The Launch of The World’s First Telehealth Platform For Psychedelic Integration
Mydecine Innovation's Mindleap subsidary launches a telehealth platform for psychedelics.
The Three Hottest Psychedelic Stocks That Every Investor Should Research
Psychedelic stocks have exploded on news of the Compass Pathways IPO. Three companies are leading the charge.
Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory
Numinus starts psilocybon cultivation operations in its 7,000 sq ft Health Canada-licensed facility.
Energized Psychedelic Stocks Showing Their Explosive Potential
After a quiet summer, trading volumes are soaring as investors pile back into psychedelic stocks.
Why Is Silicon Valley Unicorn-Hunting In Big Pharma's Backyard?
Move over Big Pharma, Here Comes Silicon Valley Investment In Psychedelics Stocks Like Compass Pathways (CMPS)
MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin
New research initiative will compare the efficacy of psilocybin with LSD.
Mind Cure adds Alain Roy as a product development specialist
Mind Cure adds a health supplements veteran to its product development team. Moonbeam mushrooms in final product testing.
Why Are Silicon Valley Billionaires Unicorn-Hunting In Psychedelics?
Move over Big Pharma, Here Comes Silicon Valley Investment In Psychedelics Stocks Like Compass Pathways (CMPS)